MYO
Myomo, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
74.00%
of MYO revenue · Direct billing customers (patients/insurance)
Myomo has 2 disclosed suppliers and 5 disclosed customers in SEC filings.
Last report3 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
No implied move.
+23.58%
vs ±59.1% implied · ×0.40
shaded = implied · ▲▼ = realized
Myomo, Inc.
1.26
SentenceRevenues generated through the direct billing channel represented 74% of revenue, increasing by 20% to $30.4 million in 2025 compared with $25.3 million in 2024.
basisMYO FY2025 revenue $41M
MYO 10-Kaccession 0001193125-26-098531
SentenceApproximately 20% and 25% of our product revenues were derived from patients with Medicare Advantage insurance plans for the years ended December 31, 2025 and 2024, respectively.
basisMYO FY2025 revenue $41M
MYO 10-Kaccession 0001193125-26-098531
SentenceWe also rely on third-party suppliers, including AB Corp, for 3D printed orthotic components.
MYO 10-Kaccession 0001193125-26-098531
SentenceA portion of these funds were used to re-pay in full the debt outstanding with Silicon Valley Bank.
MYO 10-Kaccession 0001193125-26-098531
SentenceOur direct billing revenues are concentrated with a small number of payers, including the Centers for Medicare and Medicaid Services ("CMS").
MYO 10-Kaccession 0001193125-26-098531
SentenceRevenues generated through the U.S. O&P channel represented 7% of revenues and doubled to approximately $2.9, compared with $1.5 million in 2024.
MYO 10-Kaccession 0001193125-26-098531
SentenceRevenues generated through the VA channel represented 2% of revenue and decreased 31% to approximately $0.8 million, compared with approximately $1.2 million in 2024.
MYO 10-Kaccession 0001193125-26-098531